This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

NIHR HSRIC. Reparixin for prevention of delayed graft function in pancreatic islet transplantation for type 1 diabetes mellitus. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016

Type 1 diabetes happens when the cells that make insulin in the pancreas, the islets, are destroyed. Islet cell transplantation involves extracting islet cells from the pancreas of a deceased donor and implanting them in the liver of someone with type 1 diabetes. This minor procedure is usually done twice for each transplant patient, and can be performed with minimal risk using a needle under local anaesthetic. Islet cell transplantation is suitable for patients with diabetes that is very hard to control. Once the islet cells are transplanted into the patient, proteins released by the patient's liver can cause the immune system to attack them and prevent them from working. Reparixin is a new drug that is given in a drip (directly into a vein). Some studies have suggested that reparixin may be able to prevent the islet cells from being damaged and therefore helping them to work better. If reparixin is licenced for use in the UK, it could be a new treatment option for patients with type 1 diabetes who have undergone islet cell transplantation.

Subject indexing assigned by CRD

Delayed Graft Function; Diabetes Mellitus, Type 1; Graft Survival; Humans; Islets of Langerhans Transplantation; Sulfonamides

English

England

An English language summary is available.

NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk

32016000678

11/05/2016